However, like many anti-mitotic drugs, CENPE inhibitors have had limited clinical efficacy as monotherapies, which may be attributable to “mitotic slippage” of cancer cells that experience prolonged mitotic arrest in response to such drugs. This evidence concerns the gene CENPE and cancer.